Cette traduction est en cours de préparation. En attendant, nous affichons temporairement la version originale en anglais.
Entreprise · 22/07/20241 min de lecture
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME; Correction
Traduction automatique locale · Langue originale de la source
Résumé
The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.
Langue originale de la source: Federal Register — Food and Drug AdministrationOuvrir le communiqué original →